– the leading provider of online annual reports to individual and institutional investors.

ZIOPHARM Oncology, Inc

ZIOPHARM Oncology, Inc., a biopharmaceutical company, focuses on the development and commercialization of in-licensed cancer drugs in North America. The company’s products under various clinical programs include Palifosfamide for the treatment of sarcoma, testicular cancer, head and neck cancer, lymphomas, and other solid tumors; Darinaparsin, an anti-mitochondrial compound for the treatment of acute promyelocytic leukemia, a precancerous condition; and Indibulin, a novel orally available small molecular-weight inhibitor of tubulin polymerization, as well as develops novel DNA-based biotherapeutics.

No investor fact sheets added yet
No responsibility reports added yet

Browse Reports